in life science
Become a CELS Member Today!
Most CELS events including VR Webinars include a coupon code for free individual and Start-Up (Bundled Individual) memberships, that can be used here. Join CELS now to start exploring your instant Life Science network!
How Entos pivoted into the development of a COVID vaccine
Date: Friday, February 5, 2021
Time: 11:00 am - 12:00 pm PST (Pacific Time)
Join Info: Dial-in & Web Access Information Provided with Registration Confirmation Email
Dr. John Lewis
CEO, Entos Pharmaceuticals
Dr. John Lewis is CEO of Entos Pharmaceuticals, an Edmonton-based biotechnology company developing genetic medicines using the Fusogenix drug delivery system. Entos is developing DNA-based vaccine and therapeutic countermeasures for COVID-19 using the Fusogenix platform technology.
Dr. Lewis holds the Frank and Carla Sojonky Chair in Prostate Cancer Research at the University of Alberta and is a Professor in the Department of Oncology, where he chairs the Alberta Prostate Cancer Research Initiative. Dr. John Lewis’s research interests lie in the areas of nanotechnology and imaging as they relate to infectious disease as well as chronic diseases such as aging and cancer. His group is focused mainly on the study of the spread, or metastasis, of cancer using advanced live imaging techniques.
© 2022 Canadian Entrepreneurs in Life Science. All Rights Reserved.